Viewing Study NCT06462495



Ignite Creation Date: 2024-07-17 @ 10:49 AM
Last Modification Date: 2024-10-26 @ 3:32 PM
Study NCT ID: NCT06462495
Status: RECRUITING
Last Update Posted: 2024-06-17
First Post: 2024-06-12

Brief Title: Head-to-head Comparison of 18FF-PSMA-N5 With 18FF-PSMA-1007 PETCT in PCa Diagnosis Recurrence and Metastasis
Sponsor: Anhui Provincial Hospital
Organization: Anhui Provincial Hospital

Study Overview

Official Title: Head-to-head Comparison of 18FF-PSMA-N5 With 18FF-PSMA-1007 PETCT in Prostate Cancer Diagnosis Recurrence and Metastasis a Prospective Study
Status: RECRUITING
Status Verified Date: 2024-06
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: To prospectively evaluate the radiodrug biodistribution of a novel PET imaging agent 18FF-PSMA-N5 in different organs of prostate cancer patients and its diagnostic efficacy in the diagnosis recurrence and metastasis of prostate cancer and to compare with 18FF-PSMA-1007
Detailed Description: 18FF-PSMA-N5 PETCT was used for initial assessment of prostate cancer or detection of recurrence The maximum standardized uptake value SUVmax was used to evaluate tumor uptake The sensitivity specificity the number and accuracy of lesions identified and the distribution of lesions in each organ were calculated and compared with those of 18FF-PSMA-1007 PETCT

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None